Chembio Diagnostics — Investor Presentation (May 2005)
17 slides from Chembio Diagnostics's investor presentation, May 2005
Slide 1: Chembio Diagnostics, Inc.
€YCHEMBIO DIAGNOSTICS, INC. (CEMI:OTCBB) May 2005 OCHEMBIO DIAGNOSTICS, INC
Slide 2: ! " # ## # ! ! # # ! !" ! ! !
! " # ## # ! ! # # ! !" ! ! ! # ! ! " # $ ! ! " ! !" % & ' (& ( )
Slide 3: Developer & Manufacturer of Rapid Diagnostic Tests
*&+,- . /0 1 & Developer & Manufacturer of Rapid Diagnostic Tests Established in 1985 with Lab Products Point of Care-Rapid Tests Begun in 1995 with Pregnancy Tests 1998 to 2003: HIV & TB Focus + Other Infectious Disease Tests 2004-2005 Exited Pregnancy Tests Reverse Merger, 8.25MM Series A & B, !"#
Slide 4: + *- , - # ! ! # ! - # 4*./ # !5667
+ 2 *- 3 , - # ! ! # ! - # 4*./ # !5667 !7666 - # 766666 !' 8/ , *- 39- :) 2 *# , & !; * + # % & # !# . ! # 2 # ! , ,9*- 3 . !
Slide 5: Actual Revenues 2003 vs 2004
; 0 2# 566 566< A c tu a l A c tu a l Change REV ENUES 2003 % 2004 % P re g n a n c y R e v e n u e 1 ,3 1 7 ,6 5 4 47% 8 5 7 ,0 7 5 26% -3 5 % H IV R e v e n u e 5 2 1 ,4 5 0 19% 1 ,2 4 2 ,2 9 5 38% 138% R & D & G ra n t In c o m e 2 7 5 ,7 3 0 10% 5 7 9 ,2 8 9 18% 110% O th e r R e v e n u e 7 0 3
Slide 6: *-3,% - 1& :&3&0 .;+&1 -1-- -3& % &' ( ' ( ;&;$ :
*-3,% - 1& :&3&0 .;+&1 -1-- -3& % &' ( ' ( ;&;$ 28 : % -:0 &/-0 .2 $.2&- /1&+, - &= ;&;$ 2 .%1 2>*& 0 *.$$--0 ' +.*?1 ) 4*.8&3 0 % - .1?,%0 @;2. %2&+&1 *&+& 1/. 80 & :- 1/3 ?;+ - +;0 &+&1 .2 ;0 &+&1 1: &&:- 1/- 1 & - 1/ 0 /.2-*+ 0 . 0+ 1%$ %2- 1/9 &+,0 >.;;.2 %1-- &
Slide 7: + 596< *- A7++ ;# ; ! %: 5967 : 2 $ B >
2 1 9 + 59 596< *- 32 9 9 67 A7++ ;# ; 969 67 3 ! %: 9 5967 : 2 $ B > & 2
Slide 8: Barrel Format – Sure Check HIV
FORMAT FLEXIBILITY: Barrel Format – Sure Check HIV
Slide 9: Format Flexibility: Cassette Format – HIV STAT-PAK
FORMAT FLEXIBILITY: Cassette Format — HIV STAT PAK Mew eo) 4 Alv 1/2 Stat-Pak A rapid qualitative screening test kit for the detection of antibodies to HIV 1 & 2 in human serum, plasma or whole blood Arapid qualitative screening test kit for the detection of HIV 1/2 Stat Pak is ideally suited for fi
Slide 10: All Risk Groups Clinical Study Performance
% 0 -1- 0 2-0: %++ 2>C All Risk Groups Reference Lab N= 2698 R (+) NR (-) IND R (+) 1138 2 1 Chembio NR (-) 2 1551 4 Sensitivity 99.8% Specificity 99.9% C # $,-* # #! # !- ,
Slide 11: Combo HIV/TB Test in development
2 ,9 *-3 Control Line HIV Test Line TB Test Line - HIV TB - - HIV TB + HIV + TB - HIV + TB + TB is the leading cause of HIV-related mortality. Chembio is developing a Combo HIV/TB Test using its colored latex technology
Slide 12: ; ' 1*;) 1*; A7666 % A 6666 ! ; ! , 1*; !
1 ; ' 1*;) 1*; A7666 % A 6666 ! ; ! , 1*; ! B 6 6 ! - 2 %: # . ; 3 ! ,' ,# )
Slide 13: - &0 0& % 0;2.;&2 >? -&1 & *- , ; : ; ;
- 1 &0 0& % 0;2.;&2 >? 0 -&1 & 2 *- 3 , ; : ; ; 0 $ ; . . -0 ; ; ; ! ! 0 /
Slide 14: Operations, Sales & Marketing organization
. D ?+ & ! E5 Sales & Marketing 6 0 ; 2 0 $. Finance & Research & #; ?+ Operations Administration Development ?, : # 33 6 9 F# & 2?: 2 , . Regulatory & Clinical Affairs :# / 2 ! QA & QC 8
Slide 15: A A 6EH 775 A 5 7<5 E5
. 2 566 566< 1% 0 1% / 0 / !# . !$ A 7 77 < A 6EH775 A57<5E5 A5H< < $$' # A 5 G6 7 A < 5G A EE<G H A G56 !# $$ A ' 5E G ) A ' G 5H ) A' 67 H6<) A' 6 GG )
Slide 16: Equivalent shares registered, options and warrants
- P re f A + B (C o n v . I n to E Q U IV . S H S R e g is t e r e d N o t R e g . COM M . Com m on) O P T IO N S W ARRANTS 4 6 ,3 0 0 ,3 6 9 2 1 ,5 8 3 ,5 5 3 2 4 ,7 1 6 ,8 1 6 7 ,0 4 8 ,0 8 6 1 6 ,6 8 0 ,7 1 7 1 ,3 6 7 ,2 5 0 2 1 ,2 0 4 ,3 1 6 FLOAT 4 ,1 2 6 ,9 1 5
Slide 17: / ! ;&;$ # *- 5667 % # *- *- ; 5667 # !
/ ! ;&;$ 2 # *- 3 5667 % # *- 3 *- 3 ; 5667 # ! , + , D A7++ , #
Chembio Diagnostics — Investor Presentation (May 2005) on 6ix